Abstract
ABSTRACTThere are currently no disease altering drugs available for Tauopathies such as Alzheimer’s disease, which alone is predicted to affect ~88 million people worldwide by 2050. As Tau aggregation underpins its toxicity, aggregation inhibitors are likely to have disease-modifying potential. Guided by in-silico mutagenesis studies, we developed a potent retro-inverso peptide inhibitor of Tau aggregation, RI-AG03 [Ac-rrrrrrrrGpkyk(ac)iqvGr-NH2], based on the 306VQIVYK311 hotspot. Aggregation of recombinant Tau was reduced by >90% with equimolar RI-AG03 and no fibrils were observed by EM. When added during the growth phase, RI-AG03 blocked seeded aggregation. Fluorescein-tagged RI-AG03 efficiently penetrated HEK-293 cells over 24 hours and was non-toxic at doses up to 30 μM. In transgenic Drosophila, RI-AG03 significantly improves neurodegenerative and behavioural phenotypes caused by expression of human Tau. Collectively this shows that RI-AG03 can effectively reduce Tau aggregation in vitro and block aggregation-dependent phenotypes in vivo, raising possibilities for exploring its translational potential.
Publisher
Cold Spring Harbor Laboratory
Reference95 articles.
1. World Health Organisation, “Dementia Fact sheet N°362,” 2015. [Online]. Available: http://www.who.int/mediacentre/factsheets/fs362/en/. [Accessed 02 October 2015].
2. Alzheimer’s Society, “Alzheimer’s Society,” 2020. [Online]. Available: https://www.alzheimers.org.uk/about-us/news-and-media/facts-media. [Accessed 25th October 2020].
3. The worldwide costs of dementia 2015 and comparisons with 2010;Alzheimer’s & Dementia,2017
4. Alzheimer’s Society, “Financial cost of dementia,” 2014. [Online]. Available: http://www.alzheimers.org.uk/site/scripts/documents_info.php-documentID=418. [Accessed 7th October 2015].
5. Designed Glycopeptidomimetics Disrupt Protein–Protein Interactions Mediating Amyloid β-Peptide Aggregation and Restore Neuroblastoma Cell Viability
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献